Finance

Lists
TRVN:OTCMKTS
Trevena Inc
0,066 USD
0,00%
(0,00) 1D
12-окт., 14:57:26 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRVN...
Mkt. cap
57,01 миң
Avg. vol.
210,00
Volume
9,00
52-wk high
1,50 USD
52-wk low
0,00 USD
Beta
1,07
Shares outstanding
864,00 миң
No. of employees
23
Mkt. cap
57,01 миң
Avg. vol.
210,00
Volume
9,00
52-wk high
1,50 USD
52-wk low
0,00 USD
Beta
1,07
Shares outstanding
864,00 миң
No. of employees
23
News stories
From web sources and news partners
medwatch.com
medwatch.com
·
29 мүнөт мурун
Iambic Therapeutics raises USD 150m in Nasdaq IPO
Yahoo Finance
Yahoo Finance
·
18 мүнөт мурун
3 S&P 500 Stocks We Steer Clear Of
Profile
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week. Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
About Trevena Inc
CEO-
Employees23
Founded2007
HeadquartersАтланта, Джорджия, Америка Кошмо Штаттары
Sector-
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2023-ж. дек.
2024-ж. мар.
2024-ж. июн.
2024-ж. сен.
Revenue
-82,00 миң
20,00 миң
325,00 миң
283,00 миң
Cost of goods sold
-
-
-
114,00 миң
Cost of revenue
-
-
-
114,00 миң
Research and development expenses
-
-
-
1,87 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
-
3,88 млн
Operating expense
-
-
-
5,75 млн
Total operating expenses
-
-
-
5,86 млн
Operating income
-
-
-
-5,58 млн
Other non operating income
-
-
-
479,00 миң
EBT including unusual items
-
-
-
-4,91 млн
EBT excluding unusual items
-
-
-
-4,91 млн
Income tax expense
-
-
-
30,00 миң
Effective tax rate
-
-
-
-0,61%
Other operating expenses
-
-
-
-
Net income
-
-
-
-4,94 млн
Net profit margin
-
-
-
-1 745,23%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
190,00 миң
Interest expense
-
-
-
-1,00 миң
Net interest expenses
-
-
-
189,00 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-5,48 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору